These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25278327)

  • 1. Persistence and adherence with urinary antispasmodic medications among employees and the impact of adherence on costs and absenteeism.
    Kleinman NL; Odell K; Chen CI; Atkinson A; Zou KH
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1047-56. PubMed ID: 25278327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
    Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
    Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin.
    Kleinman NL; Sadosky A; Seid J; Martin RC; Labiner DM
    Epilepsy Res; 2012 Nov; 102(1-2):13-22. PubMed ID: 22591752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of urge urinary incontinence in the workplace.
    Kleinman NL; Chen CI; Atkinson A; Odell K; Zou KH
    J Occup Environ Med; 2014 Mar; 56(3):266-9. PubMed ID: 24603202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.
    Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
    Clin Drug Investig; 2015 Dec; 35(12):795-805. PubMed ID: 26464261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis.
    Kleinman NL; Cifaldi MA; Smeeding JE; Shaw JW; Brook RA
    J Occup Environ Med; 2013 Mar; 55(3):240-4. PubMed ID: 23471034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of COVID-19 on work loss in the United States- A retrospective database analysis.
    Judy J; Yehoshua A; Gouveia-Pisano J; Brook RA; Kleinman NL; Drnach AA; Rosenberg EM; Ghanjanasak T; Winter DA; Dai F; Escobar JM; Sell H
    J Med Econ; 2024; 27(1):941-951. PubMed ID: 38984895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absenteeism and health-benefit costs among employees with MS.
    Brook RA; Rajagopalan K; Kleinman NL; Melkonian AK
    Curr Med Res Opin; 2009 Jun; 25(6):1469-76. PubMed ID: 19422277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of urgency urinary incontinence in the United States: a systematic review.
    Coyne KS; Wein A; Nicholson S; Kvasz M; Chen CI; Milsom I
    J Manag Care Pharm; 2014 Feb; 20(2):130-40. PubMed ID: 24456314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
    Qin L; Luo X; Zou KH; Snedecor SJ
    J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employees with overactive bladder: work loss burden.
    Wu EQ; Birnbaum H; Marynchenko M; Mareva M; Williamson T; Mallett D
    J Occup Environ Med; 2005 May; 47(5):439-46. PubMed ID: 15891521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic impact of bipolar disorder in an employed population from an employer perspective.
    Gardner HH; Kleinman NL; Brook RA; Rajagopalan K; Brizee TJ; Smeeding JE
    J Clin Psychiatry; 2006 Aug; 67(8):1209-18. PubMed ID: 16965198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of antihypertensive medication adherence among employees with hypertension.
    Lynch WD; Markosyan K; Melkonian AK; Pesa J; Kleinman NL
    Am J Manag Care; 2009 Dec; 15(12):871-80. PubMed ID: 20001168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing adherence and persistence across 6 chronic medication classes.
    Yeaw J; Benner JS; Walt JG; Sian S; Smith DB
    J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
    Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
    Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
    Angulo JC; Sánchez-Ballester F; Peral C; Rejas J; Ramos J; Snedecor SJ; Sudharshan L; Liu S; Luo X
    Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An employer perspective on annual employee and dependent costs for pediatric asthma.
    Kleinman NL; Brook RA; Ramachandran S
    Ann Allergy Asthma Immunol; 2009 Aug; 103(2):114-20. PubMed ID: 19739423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks.
    Lynch W; Chan W; Kleinman N; Andrews LM; Yadao AM
    Popul Health Manag; 2013 Apr; 16(2):138-45. PubMed ID: 23113634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
    Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
    Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.